# A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

> **NCT06140524** · PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 116 (estimated)

## Conditions studied

- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Smoldering Multiple Myeloma (SMM)

## Interventions

- **DRUG:** Linvoseltamab

## Key facts

- **NCT ID:** NCT06140524
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2032-05-18
- **Final completion:** 2032-05-18
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06140524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06140524, "A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06140524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*